FDA approves datopotamab deruxtecan-dlnk for unresectable or metastatic TNBC
The FDA has approved the antibody-drug conjugate for patients with unresectable or metastatic triple-negative breast cancer.
The FDA has approved datopotamab deruxtecan-dlnk for unresectable or metastatic triple-negative breast cancer1.
The approval notice does not provide further detail on the trial data, dosing, or regulatory pathway supporting the decision. Readers seeking additional specifics on the clinical evidence, prescribing information, or company statements regarding this approval should consult the full FDA announcement and related labeling documents, as this record provides only the approval action itself.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.